Rosiglitazone cools down inflammation in the metabolic syndrome [1]

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 6, 2006, Pages 1413-1414

  Esposito, Katherine ^a   Ciotola, Miryam ^a   Merante, Domenico ^b   Giugliano, Dario ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b GSK   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PIOGLITAZONE; PROTEASOME; ROSIGLITAZONE; SYNAPTOTAGMIN; UBIQUITIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; HUMAN CELL; HYPOGLYCEMIA; IN VITRO STUDY; INFLAMMATION; INSULIN RESISTANCE; LETTER; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STROKE; UBIQUITINATION; ADULT; FEMALE; HOSPITALIZATION; MALE; METABOLISM; MIDDLE AGED; NOTE;

ADULT; FEMALE; HUMANS; INFLAMMATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES;

EID: 33745020249     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000223874.94624.11     Document Type: Letter

References (13)

1. Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, Kochar A, Wolfe ML, Rader DJ. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2006;26:624-630.
2. Szapary PO, Bloedon LT, Samaha F, Duffy D, Wolfe ML, Soffer D, Reilly MP, Chittams J, Rader DJ. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol. 2006;26:182-188.
3. Esposito K, Ciotola M, Giugliano D. Inflammation warms up the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2005;25:e143.
4. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-1118.
5. Martens F-M, Visseren F-L, Lemay J, de Koning EJ, Raelink TJ. Metabolic and additional effects of thiazolodinediones. Drugs. 2002;62:1463-1480.
6. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83:1818-1820.
7. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:3452-3456.
8. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol. 2004;24:930-934.
9. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro-Vascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
10. Herrmann J, Ciechanover A, Lerman LO, Lerman A. The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended. Cardiovasc Res. 2004;61:11-21.
11. Motomura W, Takahashi N, Nagamine M, Sawamukai M, Tanno S, Kohgo Y, Okumura T. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Int J Cancer. 2004;108:41-46.
12. Executive Summary of the Third Report of the national Cholesterol Education Program (NCEP) expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP III). J Am Med Assoc. 2001;285:2486-2497.
13. Fitzsimmons C, Proudfoot D, Bowyer DE. Monocyte prostaglandins inhibit procollagen secretion by human vascular smooth muscle cells: implications for plaque stability. Atherosclerosis. 1999;142:287-293.